Fig 1: Role of Epfn activation at stage 3 in ameloblast induction. (A) Diagram of ameloblast induction from Epfn-iPSCs. Dox (1 μg/ml) was added at stage 3 to activate Epfn expression. (B) Cell morphology (upper) and mCherry expression (lower) on day 17. Scale bar: 100 μm. (C) WST-1 test on day 17. *, p < 0.05 (t-test; n = 3). (D) ARS stain on day 17. Scale bar: 1 cm. (E) Quantification of ARS staining on day 17. **, p < 0.01 (t-test; n = 3). (F) Gene expression according to RT-PCR analysis on day 17. Markers (stem cells: Oct4; dental epithelial: Krt14, p75, and tuftelin; and ameloblast: Amelx, Ambn and KLK4). (G) Relative quantitative analysis of RT-PCR results. **, p < 0.01 (t-test; n = 3). (H) Western blotting on day 17. (I) Relative quantitative analysis of Western blot results. **, p < 0.01 (t-test; n = 3). (J) Real-time PCR of the BMP-Smad signaling pathway-associated molecules on day 17. **, p < 0.01 (t-test; n = 3).
Fig 2: Overexpression of target genes following overexpression of miR-16-5p and miR-27b-3p. (A) Schematic of the experiment. (B) Gene expression of Amelx and Enam following overexpression of Eda, Relt, and Smad3 under overexpression of control and miR-16-5p mimic, or of Bmp2, Pax9, and Slc24a4 under overexpression of control and miR-27b-3p mimic, in mHAT9d cells (n = 6). *p < 0.05; **p < 0.01; ***p < 0.001. (C) ICC for AMELX in mHAT9d cells under the indicated conditions. Scale bar, 50 μm. Graph shows the quantification of images from four independent experiments. **p < 0.01; ***p < 0.001.
Fig 3: Role of Epfn activation at stages 2 and 3 in ameloblast induction. (A) Diagram of ameloblast induction from Epfn-iPSCs. Dox (1 μg/ml) was added at stages 2 and 3 to activate Epfn expression. (B) Cell morphology (upper) and mCherry expression (lower) on day 17. Scale bar: 100 μm. (C) WST-1 test on day 17. **, p < 0.01. (D) ARS stain on day 17. Scale bar: 1 cm. (E) Quantification of ARS staining on day 17. **, p < 0.01 (t-test; n = 3). (F) Gene expression according to RT-PCR analysis on day 17. Markers (stem cells: Oct4; dental epithelial: Krt14, p75, and tuftelin; and ameloblast: Amelx, Ambn and KLK4). (G) Relative quantitative analysis of RT-PCR results. **, p < 0.01 (t-test; n = 3). (H) Western blotting on day 17. (I) Relative quantitative analysis of Western blot results. *, p < 0.05; **, p < 0.01 (t-test; n = 3). (J) Real-time PCR of the BMP-Smad signaling pathway-associated molecules on day 17. **, p < 0.01 (t-test; n = 3).
Fig 4: Dysregulated signalling molecules in the ameloblasts of neonatal offspring of circadian disruption pregnant mice. An environmental circadian disruption model was constructed in 10- to 12-week-old pregnant mice. a Total protein of mandibular first molar germs of the offspring (PN3) was extracted. Compared to the control group, the protein levels of PER2, PPARγ and AMELX decreased in the disturbance group. b The mandibles of the offspring (PN5) were dissected. Compared to the control group, the expression levels of PER2, PPARγ, AKT1-Ser473 and β-catenin-Ser552 were reduced in ameloblasts in the disturbance group. **P < 0.01; ***P < 0.001. Bar = 20 μm
Fig 5: Altered histogenesis and cellular events in 1-week renal calcified teeth. H&E staining showing 1 week renal calcified teeth after loss and gain of function of miRNA-221-3p (A–C, n = 3). The inhibitor-treated tooth (B) is comparatively smaller with reduced extracellular matrix secretion compared to control and mimic (A,C). The localizations of AMELX and NESTIN are weaker in inhibitor-treated specimen compared to mimic and control (D–F, n = 3). H&E staining showing HERS in 1-week calcified teeth (G–I). The cellular proliferation (green) along the HERS is higher in the inhibitor-treated specimen compared to mimic and control (J–M, n = 3). DAPI (blue) stains the nuclei. Boxes in G–I are magnified views. Dotted lines (J–L) indicate the HERS. H&E, hematoxylin and eosin; Am, ameloblasts; Od, odontoblasts; AMELX, amelogenin; HERS, hertwig’s epithelial root sheath. Data were evaluated for statistical significance using unpaired, two-tailed t-test. ∗Indicates p < 0.05; NS, not significant. Scale bars: 200 μm (A–F), 50 μm (G–L).
Supplier Page from Abcam for Anti-AMG antibody